RESUMO
Serotonin 5-HT(1A) receptor antagonists potentiate the effects of serotonin reuptake inhibitors on extracellular serotonin levels in a variety of brain regions. These effects are quite variable, however, with reports indicating potentiations of anywhere from 100-1900%. One factor that might impact the magnitude of such potentiations is the timing of administration of the two agents; reports in which the reuptake inhibitor is given prior to the serotonin receptor antagonist consistently report larger potentiations than reports in which the antagonist is given first. To test this relationship directly, microdialysis and electrophysiology studies were performed to assess the magnitude of increase in extracellular serotonin and changes in cellular activity produced by the serotonin reuptake inhibitor fluoxetine and the 5-HT(1A) receptor antagonist WAY-100635 under various dosing regimens. In microdialysis studies, when WAY-100635 (0.5 mg/kg s.c.) was administered 80 min after fluoxetine (10 mg/kg i.p.) the increase in serotonin was more than twice that observed when the compounds were coadministered. In electrophysiology studies in vivo, WAY-100635 reversed the depression of cell firing produced by fluoxetine when administered 30 min after fluoxetine, but when the two compounds were coadministered, a depression in firing rate was observed comparable to that produced by fluoxetine alone. In contrast, slice recording studies showed that WAY-100635 blocked the effects of fluoxetine regardless of the order of administration. These results indicate that fluoxetine and WAY-100635 can interact in a fashion not predicted by the currently accepted model. It is likely that neuronal circuitry outside of the raphe nuclei underlies this relationship.
Assuntos
Esquema de Medicação , Interações Medicamentosas/fisiologia , Fluoxetina/farmacologia , Piperazinas/farmacologia , Piridinas/farmacologia , Antagonistas da Serotonina/farmacologia , Serotonina/metabolismo , Transmissão Sináptica/efeitos dos fármacos , Potenciais de Ação/efeitos dos fármacos , Potenciais de Ação/fisiologia , Animais , Relação Dose-Resposta a Droga , Eletrofisiologia , Espaço Extracelular/efeitos dos fármacos , Espaço Extracelular/metabolismo , Técnicas In Vitro , Masculino , Microdiálise , Neurônios/citologia , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Núcleos da Rafe/citologia , Núcleos da Rafe/efeitos dos fármacos , Núcleos da Rafe/metabolismo , Ratos , Ratos Long-Evans , Ratos Sprague-Dawley , Receptores de Serotonina/efeitos dos fármacos , Receptores de Serotonina/metabolismo , Receptores 5-HT1 de Serotonina , Transmissão Sináptica/fisiologia , Fatores de TempoRESUMO
Many acutely acting antimigraine drugs have the ability to constrict porcine arteriovenous anastomoses as well as the human isolated coronary artery. These two experimental models seem to serve as indicators, respectively, for the therapeutic and coronary side-effect potential of the compounds. Using these two models, we have investigated the effects of BMS-181885 (3-[3-[4-(5-methoxy-4-pyrimidyl)-1-piperazinyl]propyl]-5-(1,2-dioxo-4-me thyl-3-cyclobuten-3-yl)amino-1H-indole), a 5-HT1B/1D receptor ligand. In anaesthetised pigs, BMS-181885 (10, 30, 100 and 300 microg kg(-1)) decreased the total carotid blood flow and conduction, exclusively at the expense of the arteriovenous anastomotic fraction as the capillary fraction did in fact increase. The highest dose (300 microg kg(-1)) produced a reduction of 52+/-6% from the baseline arteriovenous anastomotic flow. When carotid haemodynamic changes after a single 100 microg kg(-1)dose of BMS-181885 or sumatriptan were studied at different time-points, BMS-188185 had a longer duration of action. Both BMS-181885 (pD2:7.9+/-0.1; Emax:9+/-3% of the contraction to 100 mM K+) and sumatriptan (pD2:6.3+/-0.1; Emax:28+/-8% of the contraction to 100 mM K+) contracted the human isolated coronary artery. The above results suggest that (i) the longer-lasting vasoconstrictor action of BMS-181885 on porcine carotid arteriovenous anastomoses may be related to its reported slow dissociation from 5-HT1B/1D receptor, and (ii) BMS-181885 should be able to abort migraine headaches in patients. It will be interesting to find out whether these properties are clinically important so that the drug exhibits less headache recurrence and coronary side-effects than sumatriptan.
Assuntos
Vasos Coronários/efeitos dos fármacos , Indóis/farmacologia , Transtornos de Enxaqueca/tratamento farmacológico , Piperazinas/farmacologia , Receptores de Serotonina/efeitos dos fármacos , Agonistas do Receptor de Serotonina/farmacologia , Vasoconstritores/farmacologia , Animais , Anastomose Arteriovenosa/efeitos dos fármacos , Anastomose Arteriovenosa/fisiologia , Artérias Carótidas/efeitos dos fármacos , Artérias Carótidas/fisiologia , Vasos Coronários/fisiologia , Hemodinâmica/efeitos dos fármacos , Humanos , Técnicas In Vitro , Indóis/toxicidade , Veias Jugulares/efeitos dos fármacos , Veias Jugulares/fisiologia , Transtornos de Enxaqueca/fisiopatologia , Contração Muscular/efeitos dos fármacos , Músculo Liso Vascular/efeitos dos fármacos , Oxigênio/sangue , Piperazinas/toxicidade , Potássio/farmacologia , Receptor 5-HT1B de Serotonina , Receptor 5-HT1D de Serotonina , Agonistas do Receptor de Serotonina/toxicidade , Substância P/farmacologia , Sumatriptana/farmacologia , Sumatriptana/toxicidade , Suínos , Vasoconstritores/toxicidadeRESUMO
Neuropeptide Y (NPY) has been implicated in the phase shifting of circadian rhythms in the hypothalamic suprachiasmatic nucleus (SCN). Using long-term, multiple-neuron recordings, we examined the direct effects and phase-shifting properties of NPY application in rat SCN slices in vitro (n = 453). Application of NPY and peptide YY to SCN slices at circadian time (CT) 7.5-8.5 produced concentration-dependent, reversible inhibition of cell firing and a subsequent significant phase advance. Several lines of evidence indicated that these two effects of NPY were mediated by different receptors. NPY-induced inhibition and phase shifting had different concentration-response relationships and very different phase-response relationships. NPY-induced phase advances, but not inhibition, were blocked by the GABAA antagonist bicuculline, suggesting that NPY-mediated modulation of GABA may be an underlying mechanism whereby NPY phase shifts the circadian clock. Application of the Y2 receptor agonists NPY 13-36 and (Cys2,8-aminooctanoic acid5,24,D-Cys27)-NPY advanced the peak of the circadian rhythm but did not inhibit cell firing. The Y1 and Y5 agonist [Leu31,Pro34]-NPY evoked a substantial inhibition of discharge but did not generate a phase shift. NPY-induced inhibition was not blocked by the specific Y1 antagonist BIBP-3226; the antagonist also had no effect on the timing of the peak of the circadian rhythm. Application of the Y5 agonist [D-Trp32]-NPY produced only direct neuronal inhibition. These are the first data to indicate that at least two functional populations of NPY receptors exist in the SCN, distinguishable on the basis of pharmacology, each mediating a different physiological response to NPY application.
Assuntos
Ritmo Circadiano/fisiologia , Neuropeptídeo Y/fisiologia , Núcleo Supraquiasmático/química , Núcleo Supraquiasmático/fisiologia , Potenciais de Ação/fisiologia , Animais , Ansiolíticos/farmacologia , Arginina/análogos & derivados , Arginina/farmacologia , Bicuculina/farmacologia , Ritmo Circadiano/efeitos dos fármacos , Eletrofisiologia , Antagonistas GABAérgicos/farmacologia , Antagonistas de Receptores de GABA-A , Masculino , Inibição Neural/efeitos dos fármacos , Inibição Neural/fisiologia , Neuropeptídeo Y/análogos & derivados , Neuropeptídeo Y/antagonistas & inibidores , Neuropeptídeo Y/farmacologia , Fragmentos de Peptídeos/farmacologia , Ratos , Ratos Endogâmicos , Receptores de Neuropeptídeo Y/agonistas , Receptores de Neuropeptídeo Y/fisiologia , Núcleo Supraquiasmático/efeitos dos fármacos , Ácido gama-Aminobutírico/fisiologiaRESUMO
Several acutely acting antimigraine drugs, including ergotamine and sumatriptan, have the ability to constrict porcine arteriovenous anastomoses as well as the human isolated coronary artery. These two experimental models seem to serve as indicators, respectively, for the therapeutic and coronary side-effect potential of the compounds. Using these two models, we have now investigated the effects of avitriptan (BMS-180048; 3-[3-[4-(5-methoxy-4-pyrimidinyl)-l-piperazinyl[propyl]-N-methyl-l H-indole-5-methane-sulfonamide monofumarate), a new 5-HT 1B/1D receptor agonist. In anaesthetized pigs, avitriptan (10, 30, 100 and 300 micrograms.kg-1) decreased the total carotid blood flow by exclusively decreasing arteriovenous anastomotic blood flow; capillary blood flow was increased. The mean +/- SEM i.v. dose of avitriptan eliciting a 50% decrease (ED50) in the porcine carotid arteriovenous anastomotic blood flow was calculated to be 76 +/- 23 micrograms.kg-1 (132 +/- 40 nmol.kg-1) and the highest dose (300 micrograms.kg-1) produced a 72 +/- 4% reduction. In recent comparative experiments (DeVries et al. 1996), the mean +/- SEM ED50 (i.v.) of sumatriptan in decreasing carotid arteriovenous anastomotic blood flow was 63 +/- 17 micrograms.kg-1 (158 +/- 43 nmol.kg-1), with a reduction of 76 +/- 4% by 300 micrograms.kg-1, i.v. Both avitriptan (pD2; 7.39 +/- 0.09; Emax: 13.0 +/- 4.5% of the contraction to 100 mM K+) and sumatriptan (pD2: 6.33 +/- 0.09; Emax: 15.5 +/- 2.3% of the contraction to 100 mM K+) contracted the human isolated coronary artery. The above results suggest that avitriptan should be able to abort migraine headaches in patients, but may exhibit sumatriptan-like effects on coronary arteries. Initial clinical studies have demonstrated the therapeutic action of the drug in acute migraine.
Assuntos
Indóis/farmacologia , Agonistas do Receptor de Serotonina/farmacologia , Sulfonamidas/farmacologia , Vasoconstritores/farmacologia , Animais , Anastomose Arteriovenosa/efeitos dos fármacos , Pressão Sanguínea/efeitos dos fármacos , Artérias Carótidas/efeitos dos fármacos , Artérias Carótidas/fisiologia , Vasos Coronários/efeitos dos fármacos , Vasos Coronários/fisiologia , Cabeça/anatomia & histologia , Cabeça/irrigação sanguínea , Frequência Cardíaca/efeitos dos fármacos , Hemodinâmica/efeitos dos fármacos , Humanos , Indóis/efeitos adversos , Transtornos de Enxaqueca/tratamento farmacológico , Contração Muscular/efeitos dos fármacos , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/fisiologia , Receptor 5-HT1B de Serotonina , Receptor 5-HT1D de Serotonina , Receptores de Serotonina/efeitos dos fármacos , Agonistas do Receptor de Serotonina/efeitos adversos , Sulfonamidas/efeitos adversos , Sumatriptana/farmacologia , Suínos , Triptaminas , Vasoconstritores/toxicidadeRESUMO
BMY-14802 (BMS-181100; alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol monohydrochloride) is a sigma receptor antagonist with potential antipsychotic activity. BMY-14802 also binds to 5-HT1A receptors and is able to inhibit the firing of dorsal raphe serotonergic neurons, suggesting that this compound has 5-HT1A receptor agonist properties in vivo. In the present study, we used in vivo microdialysis to study the effects of BMY-14802 on extracellular serotonin (5-hydroxytryptamine), 5-hydroxyindole-3-acetic acid (5-HIAA) and homovanillic acid (HVA) in the dorsal raphe and ventral hippocampus in the awake rat. Systemic injections of 5-20 mg/kg BMY-14802 induced a simultaneous dose-dependent decrease in 5-HT and markedly increased the dopamine metabolite, HVA concentrations in dialysates from dorsal raphe and hippocampus. Extracellular concentrations of the 5-HT metabolite, 5-HIAA decreased only after 20 mg/kg BMY-14802. The 5-HT decreases in dorsal raphe and hippocampus produced by BMY-14802 were completely antagonized by pretreatment with 1.0 mg/kg of the specific 5-HT1A antagonist, WAY-100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride). These data indicate that BMY-14802 decreases dorsal raphe and hippocampal release of 5-HT by interaction with somatodendritic 5-HT1A receptors in the raphe nuclei and suggest that this compound is a potential anxiolytic.
Assuntos
Ansiolíticos/farmacologia , Hipocampo/metabolismo , Pirimidinas/farmacologia , Núcleos da Rafe/metabolismo , Agonistas do Receptor de Serotonina/farmacologia , Serotonina/metabolismo , Animais , Ansiolíticos/antagonistas & inibidores , Relação Dose-Resposta a Droga , Hipocampo/efeitos dos fármacos , Ácido Homovanílico/metabolismo , Ácido Hidroxi-Indolacético/metabolismo , Masculino , Microdiálise , Piperazinas/farmacologia , Piridinas/farmacologia , Pirimidinas/antagonistas & inibidores , Núcleos da Rafe/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Antagonistas da Serotonina/farmacologiaRESUMO
In the rat hippocampus, 5-hydroxytryptamine (5-HT)1A receptors couple to two independent effector mechanisms, the inhibition of adenylyl cyclase activity and the opening of a K+ channel. In the dorsal raphe, 5-HT1A receptors also open K+ channels; however, coupling to adenylyl cyclase has not been demonstrated. In this study, the selective 5-HT1A agonists (+/-)- 8-hydroxy-2-(di-n-propylamino)tetralin, (R+)-8-hydroxy-2-(di-n-propylamino)tetralin and dipropyl-5-carboxamidotryptamine, did not inhibit forskolin-stimulated adenylyl cyclase (FSAC) activity in raphe region homogenates, although these drugs were efficacious in hippocampal homogenates. Other 5-HT1A agonists, NAN-190, BMY-7378, buspirone and gepirone, were also ineffective in raphe region homogenates. Estrogen-treatment of ovariectomized female rats, which is known to enhance 5-HT1A-mediated inhibition of FSAC in the hippocampus, did not promote the action of 5-HT1A agonists. Nor did activation of 5-HT1A receptors stimulate basal adenylyl cyclase activity in raphe homogenates as it does in the hippocampus. FSAC activity was inhibited in raphe region homogenates by activation of adenosine A1 or gamma-aminobutyric acidB receptors or by direct activation of the inhibitor G-protein, Gi, with guanyl-5'-6'-imidodiphosphate, indicating that the raphe homogenates have the biochemical machinery for inhibition of FSAC. High affinity binding studies showed that, in raphe homogenates, 5-HT1A receptors were expressed at a density comparable to that of adenosine A1 receptors and that they were coupled to G-proteins. It should be noted that our failure to observe 5-HT1A-mediated inhibition of adenylyl cyclase in the raphe does not prove that such coupling does not exist. However, a lack of 5-HT1A receptor coupling to adenylyl cyclase in the raphe would support contentions that coupling of the 5-HT1A receptor to adenylyl cyclase may be independent of its coupling to the K+ channel and that there may be distinct differences between pre- and postsynaptic 5-HT1A receptor systems.
Assuntos
Adenilil Ciclases/efeitos dos fármacos , Núcleos da Rafe/efeitos dos fármacos , Receptores de Serotonina/efeitos dos fármacos , 8-Hidroxi-2-(di-n-propilamino)tetralina/farmacologia , Animais , Relação Dose-Resposta a Droga , Feminino , Masculino , Núcleos da Rafe/enzimologia , Ratos , Ratos Sprague-DawleyRESUMO
Somatodendritic and terminal release of serotonin (5-HT) was investigated by simultaneously measuring extracellular concentrations of 5-HT, 5-hydroxyindole-3-acetic acid (5-HIAA) and homovanillic acid (HVA) in the dorsal raphé and ventral hippocampus in freely moving rats. Perfusion of tetrodotoxin (TTX, 1 microM and 10 microM) into the dorsal raphé simultaneously decreased dorsal raphé and hippocampal 5-HT release. However, following TTX perfusion into the hippocampus (10 microM), hippocampal 5-HT release was profoundly reduced but dorsal raphé 5-HT remained unchanged. Systemic injections with 5-HT1A agonist, buspirone (1.0-5.0 mg/kg, i.p.) decreased 5-HT and 5-HIAA and increased HVA concentrations in the dorsal raphé and in the hippocampus. The decreases in the raphé and hippocampal 5-HT induced by systemic buspirone were antagonized in rats pretreated with 1.0 mM (-) pindolol, locally perfused into the dorsal raphé. Local dorsal raphé perfusion of (-) pindolol alone (0.01-1.0 mM) increased dorsal raphé 5-HT and concomitantly induced a small increase in hippocampal 5-HT. Buspirone perfusion into the dorsal raphé did not change (10 nM, 100 nM), or produced a small increase (1.0 mM) in raphé 5-HT, without changing hippocampal 5-HT. These data provide evidence that 5-HT release in the dorsal raphé is dependent on the opening of fast activated sodium channels and that dorsal raphé 5-HT1A receptors control somatodendritic and hippocampal 5-HT release
Assuntos
Dendritos/metabolismo , Hipocampo/metabolismo , Terminações Nervosas/metabolismo , Núcleos da Rafe/metabolismo , Serotonina/metabolismo , Antagonistas Adrenérgicos beta/farmacologia , Animais , Buspirona/farmacologia , Dendritos/efeitos dos fármacos , Hipocampo/efeitos dos fármacos , Ácido Homovanílico/metabolismo , Ácido Hidroxi-Indolacético/metabolismo , Masculino , Microdiálise , Pindolol/farmacologia , Núcleos da Rafe/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Agonistas do Receptor de Serotonina/farmacologia , Tetrodotoxina/farmacologiaRESUMO
Nefazodone is a new antidepressant drug with a pharmacologic profile distinct from that of the tricyclic, monoamine oxidase inhibitor, and serotonin selective reuptake inhibitor antidepressants. Nefazodone was initially discovered for its ability to block 5-HT2A receptors and its reduced potency as an alpha 1-adrenergic blocker. It was later shown to inhibit both serotonin and norepinephrine uptake in vitro, attributes which most likely impart its clinical efficacy and which differentiate nefazodone from its chemical predecessor trazodone. The combination of these two mechanisms may ultimately result in a facilitation of 5-HT1A-mediated neurotransmission, which may be beneficial for treating symptoms of depression as evidenced by recent clinical findings. In addition, the preclinical profile of nefazodone demonstrates that it has decreased anticholinergic and antihistaminic activity relative to traditional agents. Clinical findings to date are consistent with these observations.
Assuntos
Antidepressivos/farmacologia , Triazóis/farmacologia , Animais , Antidepressivos/química , Antidepressivos/uso terapêutico , Comportamento Animal/efeitos dos fármacos , Transtorno Depressivo/tratamento farmacológico , Relação Dose-Resposta a Droga , Regulação para Baixo/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Humanos , Técnicas In Vitro , Nociceptores/efeitos dos fármacos , Piperazinas , Ratos , Receptores Adrenérgicos/efeitos dos fármacos , Receptores Adrenérgicos alfa/efeitos dos fármacos , Receptores de Serotonina/efeitos dos fármacos , Triazóis/química , Triazóis/uso terapêuticoRESUMO
1. The full and weak partial 5-HT1A agonist ligands [3H]-8-OH-DPAT and [3H]-BMY-7378 were used to characterize the binding parameters of pre- and postsynaptic 5-HT1A binding sites in bovine dorsal raphe and hippocampal membranes, respectively. The Kd and Bmax values for the individual radioligands were indistinguisable across the regions tested, as were the Ki values generated by a series of agents acting at 5-hydroxytryptamine (5-HT) receptors. 2. The concentration-dependent allosteric attenuation of [3H]-8-OH-DPAT and [3H]-BMY-7378 binding produced by the nonhydrolyzable guanyl nucleotide, Gpp(NH)p, generated similar IC50 values within a particular region; however, these were significantly different between regions. While the maximal attenuation of [3H]-8-OH-DPAT and [3H]-BMY-7378 binding was similar in dorsal raphe, Gpp(NH)p produced a significantly greater attenuation of [3H]-8-OH-DPAT binding in hippocampal membranes when compared to [3H]-BMY-7378. The maximal attenuation of [3H]-8-OH-DPAT binding by Gpp(NHp) in hippocampus was also significantly greater than that seen with either radioligand in dorsal raphe. 3. Although exposure to Gpp(NH)p had no effect on the affinity constants of either radioligand in either region, it produced a concentration-dependent reduction in the maximal number of binding sites for both radioligands in both regions. While the percentage reduction in Bmax values were similar for both radioligands in the dorsal raphe, Gpp(NH)p reduced the Bmax of [3H]-8-OH-DPAT in hippocampus significantly more than that of [3H]-BMY-7378. 4. These results suggest that while pre- and postsynaptic 5-HT1A receptors may share similar pharmacological recognition properties, a region-dependent difference in the coupling of the 5-HT1A receptor to G-proteins may exist.
Assuntos
Encéfalo/metabolismo , Receptores Pré-Sinápticos/metabolismo , Receptores de Serotonina/metabolismo , Agonistas do Receptor de Serotonina/metabolismo , 8-Hidroxi-2-(di-n-propilamino)tetralina/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Bovinos , Guanilil Imidodifosfato/farmacologia , Hipocampo/efeitos dos fármacos , Hipocampo/metabolismo , Técnicas In Vitro , Cinética , Piperazinas/farmacologia , Ensaio Radioligante , Núcleos da Rafe/efeitos dos fármacos , Núcleos da Rafe/metabolismo , Ratos , Receptores Pré-Sinápticos/efeitos dos fármacosRESUMO
Four human 5-HT receptor subtypes (5-HT1A, 5-HT1D alpha, 5-HT1D beta and 5-HT1E) have been expressed in Sf9 insect cells. All four human 5-hydroxytryptamine receptors produced by Sf9 cells had the expected pharmacological properties. Surprisingly, levels of expression of these receptors were relatively low (1-5 pmol/mg protein). High affinity agonist binding to the four 5-hydroxytryptamine receptors was reduced to different extents by guanine nucleotides and/or NaCl. This suggests that the nature of receptor-G protein coupling and/or the predominant conformational state of the receptors in Sf9 cell membranes varies among the different receptors. Activation of all four receptors inhibited forskolin-stimulated cAMP formation in intact Sf9 cells. Expression of 5-hydroxytryptamine receptors in Sf9 cells should be useful for purification of these receptors, for studies of post-translational modification and for pharmaceutical screening.
Assuntos
Receptores de Serotonina/metabolismo , Sequência de Aminoácidos , Animais , Baculoviridae , Linhagem Celular , Membrana Celular/metabolismo , Clonagem Molecular , Colforsina/farmacologia , AMP Cíclico/metabolismo , Proteínas de Ligação ao GTP/metabolismo , Nucleotídeos de Guanina/metabolismo , Humanos , Dados de Sequência Molecular , Mariposas , Ensaio Radioligante , Receptores de Serotonina/química , Receptores de Serotonina/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Agonistas do Receptor de Serotonina/metabolismo , Cloreto de Sódio/metabolismoRESUMO
A gene encoding a novel G protein-coupled 5-hydroxytryptamine (5-HT) receptor, termed 5-HT5B, was cloned. The ligand binding profile of this receptor is distinct from that of other cloned 5-HT receptors. The 5-HT5B receptor couples to a G protein in COS1 cell membranes; however, activation of the 5-HT5B receptor does not appear to alter either cAMP accumulation or phosphoinositide turnover in a variety of fibroblast cell lines. In the rat brain, 5-HT5B gene expression occurs predominantly in the medial habenulae and hippocampal CA1 cells of the adult. Little expression is seen during embryonic development.
Assuntos
Proteínas de Ligação ao GTP/metabolismo , Receptores de Serotonina/genética , Sequência de Aminoácidos , Animais , Sequência de Bases , Encéfalo/metabolismo , Linhagem Celular , Membrana Celular/metabolismo , Clonagem Molecular , DNA , Embrião de Mamíferos/metabolismo , Expressão Gênica , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Ligação Proteica , Ratos , Receptores de Serotonina/metabolismo , Homologia de Sequência de Aminoácidos , Distribuição TecidualRESUMO
1. [3H]-5-hydroxytryptamine (5-HT) has been shown to radiolabel at least five types of 5-HT binding sites in mammalian brain tissue, 5-HT1A, 5-HT1C, 5-HT1D and 5-HT1D and 5-HT1E (Frazer et al., 1990). Selective masking of 5-HT1A and 5-HT1C receptors, has uncovered binding sites which display both high (5-HT1D) and low (5-HT1E) affinity for 5-carboxamidotryptamine (5-CT). By utilizing [3H]-5-CT we have eliminated a portion of the complex binding (5-HT1E) seen when [3H]-5-HT is used as a radioligand. 2. [3H]-5-CT binding to 5-HT1D sites in bovine substantia nigra was rapid, reversible and saturable, displaying high affinity (Kd = 0.38 +/- 0.04 nM) and low non-specific binding (> 90% specific binding). 3. In bovine substantia nigra, [3H]-5-CT labelled an equivalent number of binding sites to [3H]-5-CT (403 +/- 18 and 362 +/- 20 fmol mg-1 protein, respectively) and binding was sensitive to guanine nucleotides. 4. A linear correlation (r2 = 0.99) existed between the potency of compounds to displace [3H]-5-HT and [3H]-5-CT in bovine substantia nigra. 5. Therefore, [3H]-5-CT is a novel radioligand for the examination of 5-HT1-like binding sites, which under proper experimental conditions can be used to radiolabel selectively 5-HT-1D-like binding sites.
Assuntos
Receptores de Serotonina/efeitos dos fármacos , Agonistas do Receptor de Serotonina/farmacologia , Serotonina/análogos & derivados , Substância Negra/metabolismo , Animais , Ligação Competitiva/efeitos dos fármacos , Bovinos , Guanilil Imidodifosfato/farmacologia , Técnicas In Vitro , Marcação por Isótopo , Membranas/efeitos dos fármacos , Membranas/metabolismo , Ensaio Radioligante , Análise de Regressão , Serotonina/farmacocinética , Serotonina/farmacologia , Agonistas do Receptor de Serotonina/farmacocinética , Substância Negra/efeitos dos fármacosRESUMO
Chronic treatment with the full 5-hydroxytryptamine1A (5-HT1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), either by twice daily subcutaneous injection (0.2 or 2.0 mg/kg) or continuous subcutaneous administration via osmotic minipumps (0.4 or 4.0 mg/kg/day), for 14 days, had no effect on the dose-response curves for inhibition of 5-hydroxytryptophan (5-HTP) accumulation in rat cortex or hippocampus by 8-OH-DPAT or the partial 5-HT1A agonist BMY 7378. In contrast, chronic treatment with the nonbenzodiazepine putative anxiolytic gepirone via osmotic minipumps (20 mg/kg/day) resulted in a small but significant rightward shift (1.8-fold) in the dose-response curve to 8-OH-DPAT challenge in the cortex and a slightly larger shift (2.4-fold) in the hippocampus. Similarly, chronic treatment with another putative anxiolytic, ipsapirone, administered via twice daily subcutaneous injections (20 mg/kg), also resulted in a rightward shift (2.6-fold) in the dose-response curve to 8-OH-DPAT in the cortex and a slightly smaller shift (2.3-fold) in the hippocampus. Neither drug, however, decreased the maximal response. The present results are consistent with the suggestion that the clinical anxiolytic effects of gepirone and ipsapirone, and not of 8-OH-DPAT, may be related to their ability to desensitize somatodendritic 5-HT1A autoreceptors; other potential mechanisms are discussed.
Assuntos
8-Hidroxi-2-(di-n-propilamino)tetralina/farmacologia , Dendritos/efeitos dos fármacos , Pirimidinas/farmacologia , Receptores de Serotonina/efeitos dos fármacos , Animais , Encéfalo/efeitos dos fármacos , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Masculino , Ratos , Ratos Sprague-DawleyRESUMO
BMY 14802 was identified as a potential antipsychotic drug in traditional model systems, and this identification was confirmed in modern behavioral and electrophysiological systems. The drug appears to be atypical as an antipsychotic in its lack of activity in models predictive of the potential to produce extrapyramidal side effects and tardive dyskinesia. Indeed, this suggestion is corroborated by clinical findings to date. The atypical profile of BMY 14802 extends to its neurochemical actions and appears to find its basis in regionally selective, indirect modulation of the dopamine system. Furthermore, BMY 14802 exhibits interactions with sigma binding sites in vitro and in vivo, a notion supported by data from neurophysiological, behavioral, and biochemical investigations. BMY 14802 also appears to be neuroprotective in some model systems and may have utility in the treatment of stroke (Boissard et al. 1991). BMY 14802 appears to interact with 5-HT1A receptors, but this interaction does not seem to contribute significantly to the potential antipsychotic actions of the drug. Moreover, the formation of active metabolites of BMY 14802 does not appear to occur in animals or humans to an extent of physiological or behavioral relevance. If clinically efficacious, BMY 14802 may treat the symptoms of schizophrenia by a mechanism novel for antipsychotic drugs: regionally selective, indirect modulation of dopaminergic systems by specific interaction at sigma sites.
Assuntos
Psicotrópicos/farmacologia , Pirimidinas/farmacologia , Receptores sigma/efeitos dos fármacos , Animais , Sítios de Ligação , Química Encefálica/efeitos dos fármacos , Humanos , Pirimidinas/efeitos adversos , Pirimidinas/uso terapêutico , Receptores sigma/metabolismoRESUMO
The ternary complex formed between agonist, receptor and guanine nucleotide binding protein and its destabilization by guanine nucleotides (GN) was utilized to study early events in signal transduction, by characterizing the allosteric interactions between agonist and GN binding to the receptor/guanine nucleotide binding protein, G complex for adenosine A1 and 5-hydroxytryptamine1A receptors. The functional interaction between the ternary complex and GTP was examined by assaying adenylyl cyclase activity. Binding of a full adenosine A1 agonist ([3H]-R-(-)-N6-(2-phenylisopropyl)adenosine), and a full [(+-)-[3H]-8-hydroxydipropylaminotetralin] and partial ([3H]-8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8- azaspirol[4.5]-decane-7,9-dione) 5-hydroxytryptamine1A agonist was examined in relation to the binding of GN. The amount of ternary complex formed depended upon receptor type and drug relative efficacy. The ratio between the drug's EC50 value (adenylyl cyclase) and dissociation constant (binding) was also receptor and drug relative efficacy dependent. 5'-Guanylylimidodiphosphate (100 microM) caused an approximately 50% decrease in the Bmax for all drugs without affecting Kd values. 5'-Guanylylimidodiphosphate and guanosine 5'-O-(3-thiotriphosphate) attenuated [3H]-agonist binding in a concentration-dependent and saturable manner, with IC50 values increased 2- to 6-fold with increasing receptor occupancy. IC50 values were approximately one-tenth lower at the 5-hydroxytryptamine1A receptor than adenosine A1 receptor; similar values were obtained for inhibition of (+-)-[3H]-8-hydroxydipropylaminotetralin and [3H]-8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8- azaspirol[4.5]-decane-7,9-dione binding, suggesting an independence of agonist efficacy. We propose that the stabilization of the ternary complex by hormone binding, measured by Bmax values, is related to drug-relative efficacy, thus the amount of ternary complex available for destabilization by GN is greater for the more efficacious agonist. This is translated into greater relative efficacy observed in the maximal inhibition of adenylyl cyclase.
Assuntos
Nucleotídeos de Guanina/farmacologia , Hipocampo/efeitos dos fármacos , Receptores Purinérgicos/efeitos dos fármacos , Receptores de Serotonina/efeitos dos fármacos , Regulação Alostérica , Animais , Sítios de Ligação , Relação Dose-Resposta a Droga , Guanosina 5'-O-(3-Tiotrifosfato)/farmacologia , Guanosina Trifosfato/farmacologia , Guanilil Imidodifosfato/farmacologia , Hipocampo/metabolismo , Técnicas In Vitro , Masculino , Ratos , Ratos Sprague-Dawley , Receptores Purinérgicos/metabolismo , Receptores de Serotonina/metabolismoRESUMO
A series of 1-(pyrimidin-2-yl)piperazine derivatives were prepared and evaluated in receptor binding assays and in in vivo behavioral paradigms as potential atypical antipsychotic agents. Compound 16 (BMS 181100 (formerly BMY 14802)) emerged as the lead compound from within the series on the basis of its good activity and duration of action in the inhibition of both conditioned avoidance responding and apomorphine-induced stereotopy in the rat. Compound 16 not only failed to induce catalepsy in the rat but was quite effective in reversing the cataleptic effect of neuroleptic agents, thus indicating a low propensity for causing extrapyramidal side effects. In comparison to reference antipsychotic agents, 16 appeared to be less sedating and was relatively weaker in causing muscle incoordination. The compound was essentially inactive in binding to dopamine D2 receptors and its chronic administration to rats did not result in dopamine receptor supersensitivity. It exhibited modest to weak affinity for 5-HT1A and alpha 1 receptors but was found to be a fairly potent ligand for sigma binding sites (IC50 vs (+)-[3H]-3-PPP = 112 nM). Although the resolved enantiomers of racemic 16 did not show dramatic differences from racemate or from each other in most tests, the R(+) enantiomer was up to 11-fold more potent than its antipode in binding to sigma sites. Several studies have indicated that 16 may be a limbic-selective agent which may modulate dopaminergic activity by an indirect mechanism. The compound has been selected for clinical evaluation in the treatment of psychosis.
Assuntos
Antipsicóticos/síntese química , Piperazinas/síntese química , Pirimidinas/síntese química , Animais , Antipsicóticos/metabolismo , Antipsicóticos/farmacologia , Aprendizagem da Esquiva/efeitos dos fármacos , Catalepsia/induzido quimicamente , Estrutura Molecular , Piperazinas/metabolismo , Piperazinas/farmacologia , Pirimidinas/metabolismo , Pirimidinas/farmacologia , Ratos , Receptores de Dopamina D2/metabolismo , Estereoisomerismo , Comportamento Estereotipado/efeitos dos fármacosRESUMO
Previous studies have demonstrated the existence of a large receptor reserve for agonists at somatodendritic 5-hydroxytryptamine1A (5-HT1A) serotonin receptors in the raphe nuclei of the rat. 5-HT1A agonists with anxiolytic properties (e.g., buspirone, gepirone, and ipsapirone) display full intrinsic activity at these receptors but are partial agonists at postsynaptic 5-HT1A receptors, which suggests that the latter sites may be devoid of a receptor reserve. In the present studies, this was directly determined by examining the relationship between receptor occupancy and response at postsynaptic 5-HT1A receptors, in rat hippocampus, mediating the inhibition of forskolin-stimulated adenylyl cyclase activity, using the method of partial irreversible receptor inactivation. Rats were treated with vehicle or the irreversible antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), and 24 hr later hippocampi were removed for saturation analysis of [3H]8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) binding to 5-HT1A receptors or for adenylyl cyclase assays. EEDQ (1 and 6 mg/kg) dose-dependently reduced the maximal number of [3H]8-OH-DPAT binding sites by 68.5 and 80%, respectively, without altering the Kd. Concentration-response curves were generated for inhibition of forskolin-stimulated adenylyl cyclase activity by 5-HT and the selective 5-HT1A agonist N,N-dipropyl-5-carboxamidotryptamine (DP-5-CT). EEDQ treatment dose-dependently reduced the maximal inhibitory effect of 5-HT [percentage of inhibition: control, 23.6; EEDQ (1 mg/kg), 13.4; EEDQ (6 mg/kg), 8.9], without altering either the slope factor (1.01) or the EC50 (96.4 nM). Analogous results were obtained with DP-5-CT [percentage of maximal inhibition: control, 24.1; EEDQ (1 mg/kg), 15.2; EEDQ (6 mg/kg), 10.7), again without changes in slope factor (0.89) or EC50 (9.9 nM). Analysis of double-reciprocal plots of equieffective concentrations of agonist, followed by calculation of fractional receptor occupancy, revealed a linear relationship between receptor occupancy and response for both 5-HT and DP-5-CT (i.e., an absence of receptor reserve). The receptor specificity of the effect of EEDQ was demonstrated in two ways. First, it was shown that pretreatment of rats with the selective 5-HT1A partial agonist BMY 7378 (10 mg/kg) before EEDQ afforded substantial protection (about 75%) against loss of the inhibitory effect of DP-5-CT on forskolin-stimulated adenylyl cyclase activity. Second, EEDQ did not alter the inhibition of forskolin-stimulated adenylyl cyclase activity induced by the adenosine A1 receptor agonist phenylisopropyladenosine (PIA).(ABSTRACT TRUNCATED AT 400 WORDS)
Assuntos
Adenilil Ciclases/metabolismo , Hipocampo/ultraestrutura , Receptores de Serotonina/fisiologia , Sinapses/ultraestrutura , 8-Hidroxi-2-(di-n-propilamino)tetralina , Adenilil Ciclases/efeitos dos fármacos , Antagonistas Adrenérgicos alfa/farmacologia , Animais , Colforsina/antagonistas & inibidores , Colforsina/farmacologia , Hipocampo/enzimologia , Hipocampo/fisiologia , Masculino , Membranas/enzimologia , Membranas/metabolismo , Quinolinas/farmacologia , Ratos , Ratos Endogâmicos , Receptores de Serotonina/metabolismo , Serotonina/farmacologia , Estimulação Química , Especificidade por Substrato , Sinapses/fisiologia , Tetra-Hidronaftalenos/metabolismo , Triptaminas/farmacologiaAssuntos
Encéfalo/ultraestrutura , Receptores de Serotonina/metabolismo , Serotonina/análogos & derivados , Animais , Sítios de Ligação , Ligação Competitiva , Encéfalo/metabolismo , Córtex Cerebral/metabolismo , Córtex Cerebral/ultraestrutura , Corpo Estriado/metabolismo , Corpo Estriado/ultraestrutura , Cobaias , Técnicas In Vitro , Ensaio Radioligante , Serotonina/metabolismo , TrítioRESUMO
Encainide is a class 1C antiarrhythmic agent that is indicated for the treatment of life-threatening arrhythmias, such as sustained ventricular tachycardia. Furthermore, encainide possesses a moderate degree of antiserotonin activity, which was quantitated in this present study by determining displacement of [3H]spiperone binding from rat cortical 5-HT2 binding sites. The Ki for encainide in this model was 66.1 nM, compared to 2.6 nM for ketanserin. Two encainide metabolites, ODE and MODE, were also active, but were weaker than encainide. Additionally, these agents were found to inhibit platelet aggregation induced in vitro in human platelet-rich plasma by the combination of ADP and serotonin. In view of the fact that serotonin is one of a variety of humoral factors capable of activating blood platelets and has been recently implicated as playing a role in certain thrombotic syndromes, encainide, along with its two principal human metabolites, ODE and MODE, and another class 1C antiarrhythmic, flecainide, were evaluated in an in vivo model of intravascular thrombosis. Intraduodenal doses of 1 mg/kg of either encainide, ODE, or MODE significantly inhibited thrombosis in a canine model of coronary artery stenosis-occlusion.
Assuntos
Anilidas/farmacologia , Antiarrítmicos/farmacologia , Trombose Coronária/sangue , Flecainida/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Difosfato de Adenosina/farmacologia , Animais , Circulação Coronária/efeitos dos fármacos , Modelos Animais de Doenças , Cães , Encainida , Frequência Cardíaca/efeitos dos fármacos , Inibidores da Agregação Plaquetária/farmacologia , Serotonina/farmacologia , Função Ventricular Esquerda/efeitos dos fármacosRESUMO
Chronic (14 day) administration of several pharmacologically-distinct antidepressant drugs resulted in marked reductions in the serotonin2 (5-HT2)-mediated quipazine-induced head shake response which were accompanied by significant reductions in the density of cortical beta-adrenergic and 5-HT2 binding sites. Noradrenergic (DSP4[N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine]-induced) and serotonergic (5,7-DHT[5,7-dihydroxytryptamine]-induced) lesions either attenuated or blocked antidepressant-induced reductions in 5-HT2-mediated behavior. DSP4- and 5,7-DHT lesions did not alter the down-regulation of 5-HT2 binding sites produced by imipramine, desipramine, phenelzine or iprindole. To a large extent, the antagonism of antidepressant-induced reductions in 5-HT2-mediated behavior was coincident with the blockade of down-regulation of beta-adrenergic binding sites by both noradrenergic and serotonergic denervation. The functional interrelationship of 5-HT2 and beta-adrenergic receptors suggested by the present findings may provide insight into a common mechanism underlying the action of pharmacologically-distinct antidepressant drugs.